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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common prima-
ry liver malignancy and constitutes over 5% of all cancers.1,2 Its 
worldwide incidence is estimated at 500000 to 1 million new 
cases per year.3 The development of HCC has a multi-step car-
cinogenetic process similar to other solid tumors; however, it 
possesses unique risk factors. Hepatitis B (HBV) or C (HCV) 
viral infection, heavy alcohol intake, prolonged dietary expo-
sure to aflatoxin or vinyl chloride, and primary hemochroma-
tosis are all associated with HCC development.4 Patients with 
HCC usually have at least one of these risk factors and their 
prevalence varies between patients according to their geo-
graphical origin.5 This HCC manifestation diversity is also 
found at the genetic and epigenetic level, and a large number 
of these alterations have been described in the literature.6 Of 
these, alterations in Wnt/β-catenin signaling have been 
proved to play a critical role in HCC development.7 Therefore, 
comprehensive knowledge of the Wnt/β-catenin signaling 
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pathway is essential to identify potential endogenous molecu-
lar targets of novel drugs.
Secreted Wnt antagonists play important roles in regulating 
Wnt/β-catenin signaling.8-10 Of these, dickkopf-1 (DKK-1), a 
prototypical member of a secreted protein family, has been 
known as a potent antagonist of Wnt/β-catenin signaling.10,11 
DKK-1 acts as an inhibitory ligand of the low-density lipopro-
tein receptor-related protein 5/6 co-receptors and subsequent-
ly blocks their interaction with Wnt, resulting in β-catenin deg-
radation.12-14 It has been reported that DKK-1 is down-regulated 
in human colon tumors, indicating that DKK-1 may act as a 
tumor suppressor and that high DKK-1 expression indicated 
favorable responses to chemotherapy in brain tumors.15,16
Conversely, DKK-1 overexpression was found in human hep-
atoblastomas, Wilms’ tumors, and multiple myelomas.17,18 In 
addition, Forget, et al. reported high DKK-1 expression in 21 out 
of 73 cases of breast cancer, particularly in hormone-resistant 
breast tumors, and several experimental studies have shown 
that DKK-1 was highly expressed in HCC.20,21 Another study 
showed that DKK-1 expression was significantly higher in spec-
imens with poorer pathologic grade and higher 18F-fluorode-
oxyglucose positron emission tomography uptake in HCC.22 
Furthermore, a recent study reported that elevated DKK-1 ex-
pression is a critical event in HCC patients, indicating poor clin-
ical outcomes, and that DKK-1 is a novel prognostic predictor in 
these patients.23 All these studies suggest that DKK-1 is associ-
ated with tumor growth and poor prognosis in some malig-
nant tumors.
The controversies regarding the molecular and clinical im-
plications of DKK-1 molecules remain unresolved. In this 
study, therefore, we investigated the role of DKK-1 in the Wnt/
β-catenin signaling pathway using several HCC cell lines and 
compared the diagnostic accuracy of serum DKK-1 to the con-
ventional HCC tumor markers, alpha-fetoprotein (AFP) and 
des-gamma-carboxy prothrombin (DCP) in human patients.
MATERIALS AND METHODS
Cell lines
Hep3B and 293 cells were grown in modified Eagle’s medium 
(MEM, GIBCO BRL, Grand Island, NY, USA). Huh7 was grown 
in Dulbecco’s MEM (DMEM, GIBCO BRL) supplemented with 
10% fetal bovine serum (GIBCO BRL), 2 mM glutamine, 100 U/
mL penicillin and 100 μg/mL streptomycin. All cells were cul-
tured at 37°C in a 5% CO2 atmosphere.
Patients and specimens
All serum samples were collected from Yonsei Liver Blood 
Bank (YLBB) system (approval number, 4-2009-0725), Sever-
ance Hospital, Sinchon-dong, Korea. This study was approved 
by the independent Institutional Review Board (IRB) of Sever-
ance Hospital and conformed to the 1975 Helsinki declaration 
ethical guidelines. 
Our exclusion criteria were as follows: 1) previous history of 
anti-HCC treatment (n=25), 2) pathological or radiological ev-
idence of mixed HCC-cholangiocellular carcinoma (n=5), 3) 
insufficient clinical data (n=2), and 4) insufficient serum sam-
ples (n=10). Serum samples from 80 HCC patients who un-
derwent surgical resection, 137 HCC patients who received 
non-surgical anti-HCC treatments (chemotherapy, radiother-
apy, ablation, and conservative care), 67 patients with liver cir-
rhosis alone, 46 patients with chronic hepatitis alone, and 40 
healthy subjects with no evidence of viral hepatitis [HBV sur-
face antigen (HBsAg) and HCV antibody negative and normal 
liver biochemistry] were collected between February 2010 
and April 2011.
Diagnosis and grading of HCC and liver cirrhosis
HCC diagnosis was made on the following criteria: 1) patho-
logical HCC diagnosis for patients who underwent surgical re-
section or percutaneous biopsy or 2) clinical and radiological 
HCC diagnosis for patients without available HCC tissue speci-
mens, based on the guidelines of the American Association for 
the Study of Liver Diseases.24 In the surgical resection cases, 
Tumor-Node-Metastasis (TNM) staging based on the Ameri-
can Joint Commission on Cancer (7th edition) was assessed 
postoperatively.25 Otherwise, HCC stage was clinically defined 
according to the Barcelona Clinic Liver Cancer (BCLC) stag-
ing system.26 For this study, early-stage HCC was defined as 
HCCs with TNM I–II and BCLC A–B.
Liver cirrhosis was histologically or clinically diagnosed as 
follows: 1) platelet count <100000/μL and ultrasonographic 
findings suggestive of cirrhosis, including a blunted, nodular 
liver edge accompanied by splenomegaly (>12 cm), 2) esoph-
ageal or gastric varices, or 3) overt liver cirrhosis complications, 
including ascites, variceal bleeding, and hepatic encephalop-
athy.27,28 Liver function was graded according to the Child-
Pugh classification.
Microscopic assessment of HCC and background liver 
histology
During histological examinations, tumor differentiation was 
classified according to the Edmondson grading system. Mi-
crovascular invasion was defined as a tumor within the vascu-
lar space of a capillary in the tumor capsule or the sinusoidal 
space of a non-tumoral liver that was visible only upon micros-
copy. Portal vein invasion was defined as a tumor within the 
vascular space of a portal vein in the portal tract of a non-tu-
moral liver that was visible only upon microscopy.29 Satellite 
nodules were defined as HCC nodules that existed in the same 
segment of the main tumor, but remained separated by an in-
terval of non-tumoral liver parenchyma.30 Background liver 
histology was evaluated semiquantitatively according to the 
Batts and Ludwig31 scoring system. Fibrosis was staged on a 0 
to 4 scale: F0, no fibrosis; F1, portal fibrosis without septa; F2, 
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portal fibrosis with a few septa; F3, numerous septa without 
cirrhosis; and F4, cirrhosis. Activity was graded as A0, none; 
A1, minimal; A2, mild; A3, moderate; and A4, severe activity.
Reverse transcription-polymerase chain reaction (RT-
PCR) 
Total RNA was isolated using an RNeasy kit (Qiagen, Santa 
Clarita, CA, USA). cDNA was synthesized by reverse transcrip-
tion with 1μg of total RNA, 0.5 μg of random hexamers (Pro-
mega, Madison, WI, USA), 1.25 mM dNTP (Boehringer-Man-
nheim, Mannheim, Germany), and 200 U Moloney murine le-
ukemia virus reverse transcriptase (MMLV-RT, Invitrogen, Carl-
sbad, CA, USA) in a 20 μL reaction volume. Polymerase chain 
reaction (PCR) was performed with 3 μL of cDNA, 10 pmol of 
the primer sets, 0.25 mM dNTP, and 2 U of Taq polymerase 
(Perkin-Elmer, Norwalk, CT, USA). PCR cycling conditions 
were as follows: 23–35 cycles of denaturation at 94°C for 30 s, 
annealing at 56–60°C for 30 s, and extension at 72°C for 30 s. 
The primer sequences used were as follows: DKK-1-forward, 
5’-TCACACCAAAGGACAAGAAG-3’; DKK-1-reverse, 5’-ATCT 
TGGACCAGAAGTGTCTAGC-3’; β-catenin-forward, 5’-ACAA 
ACTGTTTTGAAAATCCA-3’; β-catenin-reverse, 5’-CGAGT 
CATTGCATACTGTCC-3’; GAPDH-forward, 5’-GCACTCAG 
GCTGAGAAC-3’; and GAPDH-reverse, 5’-GGTGAAGACGC 
CAGTGGA-3’. PCR products were analyzed by agarose gel 
electrophoresis.
Luciferase assay
To evaluate TCF-4/β-catenin transcriptional activity, the lucif-
erase reporter assay was performed using the luciferase re-
porter constructs, TOPflash and FOPflash. TOPflash contains 
three copies of the TCF-4 binding site and FOPflash contains 
mutated TCF-4 binding sites. Hep3B and 293 cells were cul-
tured to 70% confluence in 24-well plates. Then, TOPflash and 
FOPflash plasmids were transfected using Fugene HD Re-
agent (Promega) according to the manufacturer’s instructions. 
Following transfection, the luciferase activity was determined 
using the dual-luciferase reporter assay system (Promega). All 
luciferase activities were normalized to renilla luciferase activ-
ity (internal control) using a luminometer (Centro XS3 LB960, 
Berthold.Tec, Bad Wildbad, Germany). Luciferase assay data 
from three independent experiments were analyzed.
DKK-1 over-expression and knock-down
For DKK-1 overexpression, 293 and Huh7 cells were transfect-
ed with either pcDNA3.1-Luciferase (control) or the same 
vector containing the DKK-1 coding sequence. Briefly, cells 
were seeded into plates and grown for 24 h until they reached 
50–60% confluence, followed by transfection with the DKK-1 
or control vector using the Fugene HD transfection reagent. 
DKK-1 overexpression was confirmed using ELISA (R&D Sys-
tems, Minneapolis, MN, USA). Small interfering RNA (siRNA) 
were transfected when the cells reached 70% confluence. The 
DKK-1 siRNAs (siDKK-1, NM012242) and GFP siRNA (siGFP, 
SP-2011) were purchased from Bioneer (Daejeon, Korea). Ex-
periments were conducted using Fugene HD transfection re-
agent and 100 nM siRNA. The DKK-1 knockdown was con-
firmed using ELISA and measured at 450 nm using a 
spectrophotometric microplate reader (Molecular Devices, 
Toronto, Canada).
Wound healing and invasion assays
For the wound healing assay, Huh7 or 293 cells were seeded 
into 35 mm dishes (Corning, NY, USA). Once the cells reached 
100% confluence, wound healing assays were performed by 
scratching a sterile pipette tip through the confluent mono-
layer. The cells were then washed, and cultured for another 24 
h before microscopic observation (Olympus America, Mel-
ville, NY, USA) at 40× magnification. The wound healing assay 
was performed in triplicate.
For the trans-well invasion assay, 1×105 Huh7 cells in se-
rum-free medium were placed into the upper chamber of the 
trans-well insert (Corning Costar, Cambridge, MA, USA) with 
Matrigel (BD Biosciences, San Jose, MA, USA). After 24 h of 
incubation at 37°C, the cells in the upper chamber and mem-
brane were removed, the remaining cells stained with hema-
toxylin (Dako, Carpinteria, CA, USA) and eosin (Sigma, ST. 
Louis, MO, USA), and the number of cells adhering to the 
lower membrane of the inserts was counted. For each experi-
mental group, the invasion assay was performed in triplicate. 
Three randomly selected fields in each replicate were chosen 
for cell number quantification.
Cell growth assay
Cell growth in Huh7 cells was analyzed using the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. Briefly, cells were seeded into a 96-well plate, left over-
night to adhere, and treated with siDKK-1. Following treat-
ment, 50 μL of MTT solution (2 mg/mL in PBS) was added to 
each well and incubated for 4 h at 37°C. The supernatant was 
discarded and 150 μL of dimethyl sulfoxide (Sigma) was added. 
The plates were agitated until the crystals dissolved. Reduced 
MTT was measured spectrophotometrically at 595 nm in a 
beam microplate reader (Molecular Devices).
Serum sample analysis
Peripheral blood samples collected into anticoagulant-free 
tubes were centrifuged and stored at -70°C prior to testing. An 
experienced researcher at Severance Hospital performed the 
assays for serum DKK-1. This individual had no access to pa-
tients’ clinical information. ELISA (R&D Systems) was per-
formed according to the manufacturer’s recommendations. 
Briefly, 96-well Nunc-Immunomicrotitre plates with a Maxi-
Sorp surface (NalgeNunc, Penfield, NY, USA) were coated 
with the DKK-1 monoclonal antibody supplied with the kit 
and incubated overnight at 4°C. The reaction was blocked 
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with 1% bovine serum albumin. Sera, diluted with 10% neo-
natal calf serum, were incubated for 2 h at 37°C. The biotinylat-
ed goat anti-human DKK-1 detection antibody was incubated 
for 2 h at 37°C, followed by streptavidin-horseradish peroxi-
dase for 20 min. Colour development was initiated with 3,3, 
5,5-tetramethylbenzidine and hydrogen peroxide followed by 
1 M sulphuric acid to stop the reaction. The optical density was 
measured at 450 nm and referenced to 570 nm on a Synergy 2 
multimode platereader (Biotek, Winooski, VT, USA). The DKK-
1 concentrations were obtained with a four-parameter logistic 
curve fitted against a standard curve and multiplied by the di-
lution factor. When the DKK-1 concentration was less than 0.03 
ng/mL (the lower limit of the standard curve), the value was 
defined as zero. All measurements were performed in triplicate.
AFP concentrations were measured by a UniCel DxI 800 Ac-
cessimmunoanalyzer (Beckman Coulter, Inc., Fullerton, CA, 
USA). Serum DCP concentrations were measured using two 
different assays: the commercially available EIA (Haicatch PIV-
KA-II, Eisai Co., Ltd., Tokyo, Japan) and a Lumipulse G1200 au-
toanalyzer (Fujirebioinc., Tokyo, Japan) according to the man-
ufacturers’ instructions. All AFP and DCP measurements were 
performed in triplicate. 
Statistical analyses
Data are expressed as mean±SD, median (range), or n (%) 
where appropriate. The statistical significance of differences 
between continuous and categorical variables was examined 
using the Student’s t-test or Mann-Whitney test, and the chi-
squared test or Fisher’s exact test, when appropriate. Receiver 
operating characteristics (ROC) curves were constructed to 
assess sensitivity, specificity, and respective areas under the 
curves (AUCs) with a 95% confidence interval (CI). The statis-
tical significance between AUC curves were calculated based 
on DeLong methods. The optimum diagnosis cutoff value was 
calculated to maximize the sum of sensitivity and specificity, 
and to minimize overall error. To determine the diagnostic ac-
curacy of DKK-1, AFP, and DCP measurements, we estimated 
the combined marker functions by binary logistic regression. 
The function values were used as one marker and subjected 
to ROC analysis. To assess whether the DKK-1, AFP, and DCP 
combination marker was better than the individual biomark-
ers, we created a new variable predicted probability (p) for 
HCC on the basis of a binary logistic regression equation. The 
combination formula (DKK-1 plus AFP, DKK-1 plus DCP, and 
DKK-1 plus AFP plus DCP) indicated simple addition of the 
value of each component, not dichotomized categorization of 
each variable (positive vs. negative). The correlation between 
DKK-1 serum concentrations and clinic-pathological charac-
teristics was analyzed with a Spearman’s rank correlation test. 
All statistical analyses were assessed using the Statistical Pack-
age for Social Science (SPSS version 20.0, Armonk, NY, USA). 
A p-value<0.05 was considered statistically significant.
RESULTS
DKK-1 expression in Hep3B, Huh7, and 283 cells
To determine the DKK-1 expression in HCC cells, reverse tran-
scription-PCR (RT-PCR) and ELISA were performed in Hep3B 
and Huh7 cells with 293 cells as a negative control. RT-PCR 
analysis showed high DKK-1 mRNA expression in Hep3B cells 
and low in 293 cells (Fig. 1A). Consistent with these findings, 
the secreted DKK-1 concentration in the culture media was 
high in Hep3B cells, moderate in Huh7 cells, and low in 293 
cells (Fig. 1B). Luciferase assays revealed that β-catenin tran-
scriptional activity increased significantly in 293 cells (ap-
proximately 2.5-fold) following DKK-1 overexpression. In 
Hep3B cells, however, the activity remained comparable be-
tween mock and DKK-1 overexpression (Fig. 1C).
DKK-1 effects on wound healing and invasivity
To investigate the effect of DKK-1 on cell migration and inva-
Fig. 1. DKK-1 expression in Hep3B, Huh7, and 293 cells. (A) RT-PCR analysis showed high DKK-1 mRNA expression in Hep3B cells, low in 293 cells, 
and none in the negative control. (B) The DKK-1 concentration secreted in the culture media, determined by ELISA, was high in Hep3B cells, moder-
ate in Huh7 cells, and low in 293 cells. (C) Following DKK-1 transfection, luciferase assays revealed that the β-catenin transcriptional activity was in-
duced in 293 cells. *p<0.01. DKK-1, dickkopf-1.
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sion capability, DKK-1 was overexpressed or knock-downed in 
293 or Huh7 cells, with low or moderate DKK-1 secretion lev-
els, respectively. In this assay, Huh7 cells with DKK-1 moderate 
expression, instead of Hep3B with high DKK-1 secretion, were 
used to prevent the potential masking of knock-down influ-
ence due to significantly high DKK-1 secretion in Hep3B cells.
Wound healing assays showed that DKK-1 overexpression 
efficiently promoted migration of 293 cells (Fig. 2A), whereas 
DKK-1 knock-down significantly inhibited Huh7 cell migra-
tion (Fig. 2B) compared with mock controls. Similarly, invasion 
assays with Huh7 cells showed that DKK-1 overexpression 
promoted invasion, whereas DKK-1 knock-down inhibited the 
invasion (Fig. 2C). MTT assays showed that the DKK-1 knock-
down significantly inhibited Huh7 cell growth after 48 h, and 
Fig. 2. DKK-1 promotes cell migration and invasion. (A) DKK-1 overexpression promoted 293 cell migration in wound healing assays. (B) DKK-1 knock-
down inhibited Huh7 cell migration in wound healing assays. (C) DKK-1 overexpression promoted Huh7 cell invasion, whereas DKK-1 knock-down in-
hibited it in invasion assays. *p<0.01. DKK-1, dickkopf-1.
120
100
80
60
40
20
0
Incubation time (h)
0 12 24
W
ou
nd
 w
id
th
 (%
)
Mock
DKK-1
*
0 12 24 h
DK
K-
1
29
3
M
oc
k
A
120
100
80
60
40
20
0
Incubation time (h)
0 12 24
W
ou
nd
 w
id
th
 (%
)
siGFP
siDKK-1
**
0 12 24 h
siD
KK
-1
Hu
h7
siG
FP
B
250
200
150
100
50
0
250
200
150
100
50
0
Mock siGFPDKK-1 siDKK-1
In
va
siv
en
es
s (
%
)
In
va
siv
en
es
s (
%
)
*
*
Mock
siGFP
DKK-1
siDKK-1
Hu
h7
C
1301http://dx.doi.org/10.3349/ymj.2015.56.5.1296
Seung Up Kim, et al.
the amount of secreted DKK-1 significantly decreased (Fig. 3).
Baseline study population characteristics
Baseline study population characteristics are described in Sup-
plementary Table 1 (only online). The age and proportion of 
male participants were statistically similar between HCC pa-
tients and controls (p>0.05). However, some factors were sig-
nificantly higher in HCC patients when compared with con-
trols, including alanine aminotransferase level (mean 54.6 IU/L 
vs. 32.3 IU/L), proportion of patients with liver cirrhosis (76.4% 
vs. 43.8%), and HBsAg positivity (85.3% vs. 59.9%) (all p<0.05). 
Serum DKK-1 levels in HCC patients and controls
To compare serum DKK-1 levels, the DKK-1 concentration 
was measured using a commercially available ELISA kit (Fig. 
4). Serum DKK-1 concentrations were significantly higher in 
all HCC patients [patients who underwent surgical resection 
(n=80) and those who were treated with other modalities 
(n=137); total n=217; median 1.48 (range 0.03–8.88) ng/mL] 
than in the three control groups [healthy subjects (n=40), pa-
tients with chronic hepatitis (n=46), and those with liver cir-
rhosis (n=67); total n=153; median 0.85 (range 0.01–2.92); p< 
0.001]. Among three control groups, DKK-1 levels were statis-
tically similar [median 0.90 (range 0.01–1.91) ng/mL in healthy 
subjects vs. 0.72 (range 0.05–2.03) ng/mL in chronic hepatitis 
patients vs. 0.81 (range 0.01–2.92) ng/mL in liver cirrhosis pa-
tients; all p>0.05].
We also measured serum AFP and DCP concentration. 
Similar to the DKK-1 results, AFP and DCP levels were signifi-
cantly higher in HCC patients than in the control groups (me-
dian 39.1 ng/mL vs. 3.3 ng/mL, p=0.011 and 129 mAU/mL vs. 22 
mAU/mL, p=0.001 for AFP and DCP, respectively) (Table 1).
Serum DKK-1 levels according to tumor stage
To investigate the correlation between serum DKK-1 concen-
tration and HCC progression, patients with HCC were classified 
according to TNM and BCLC staging. The serum DKK-1 levels 
of HCC patients according to tumor stage are as shown in Table 
1 and Fig. 4. The HCC patients were stratified into early- and 
advanced-stage HCC [TNM I–II (n=144) vs. TNM III–IV (n=73)]. 
DKK-1 levels in TNM I–II patients tended to be lower than 
TNM III–IV patients (median 1.37 ng/mL vs. 1.66 ng/mL; p= 
0.093). DCP levels were significantly lower (median 61 mAU/
mL vs. 1112 mAU/mL; p=0.009), whereas AFP levels were sta-
tistically similar (median 30.8 ng/mL vs. 46.4 ng/mL; 
p=0.516). When the BCLC staging system was applied, DKK-1 
levels were significantly lower in BCLC A–B patients (n=146) 
than in BCLC C–D patients (n=71) (median 1.36 ng/mL vs. 
1.73 ng/mL; p=0.014). DCP level was significantly lower (me-
dian 64 mAU/mL vs. 579 mAU/mL; p=0.019), whereas AFP 
was not statistically significant (median 46.35 ng/mL vs. 27.9 
Fig. 3. Knock-down of DKK-1 inhibits cell growth. (A) DKK-1 knock-down in Huh7 cells decreased the amount of secreted DKK-1 after 48 h, deter-
mined by ELISA. (B) DKK-1 knock-down inhibited Huh7 cell growth after 48 h, determined by MTT assays. *p<0.01. DKK-1, dickkopf-1.
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ng/mL; p=0.690).
Compared to controls (median 0.90 ng/mL), DKK-1 level in 
early-stage HCC patients (graded TNM I–II and BCLC A–B) 
were significantly higher (median 1.37 ng/mL and 1.36 ng/
mL, respectively; all p<0.001). Similarly, AFP and DCP levels 
were significantly different between controls and TNM I–II 
(p=0.038 and p<0.001) and BCLC A–B stage patients (p=0.046 
and p<0.001) (Table 1).
Diagnostic accuracy of DKK-1, AFP, and DCP
The optimum DKK-1 cutoff value was calculated as 1.01 ng/
mL (AUC=0.829; 95% CI, 0.784–0.875; sensitivity, 90.7%; speci-
ficity, 62.0%), AFP as 7.5 ng/mL (AUC=0.794; 95% CI, 0.746–
0.841; sensitivity, 69.3%; specificity, 87.6%), and DCP as 40.5 
mAU/mL (AUC=0.815; 95% CI, 0.771–0.859; sensitivity, 66.5%; 
specificity, 93.4%). The AFP and DCP cutoff values were simi-
lar to our institution’s recommended clinical cutoff value (10 
ng/mL and 35 mAU/mL, respectively). For ease of interpreta-
tion, we adopted 1.00 ng/mL (sensitivity and specificity iden-
tical to 1.01 ng/mL), 10 ng/mL (sensitivity, 65.1% and specific-
ity, 89.8%), and 40 mAU/mL (sensitivity and specificity 
identical to 40.5 mAU/mL) as the DKK-1, AFP, and DCP cutoff 
values, respectively.
The diagnostic indices and corresponding ROC curves us-
ing these cutoff values are shown in Table 2, Supplementary 
Fig. 1 (only online). In the differential diagnostic accuracy as-
sessment, DKK-1 had a greater AUC for identifying HCC from 
the controls than AFP and DCP (AUC=0.829 vs. 0.794 and 0.815, 
respectively) (Table 2, Supplementary Fig. 1A, only online). 
However, the AUCs of three markers were statistically similar 
(all p>0.05). Because DKK-1, AFP, and DCP had no statistical 
correlations (all p>0.05 by Pearson correlation analysis), we 
combined these tumor markers to determine whether the di-
agnostic accuracy could be enhanced. The accuracy of DKK-1 
plus AFP or DKK-1 plus DCP was significantly higher than 
DKK-1 alone (AUC=0.901 vs. 0.829, p<0.001 and 0.927 vs. 0.829, 
p<0.001, respectively). Furthermore, the accuracy of DKK-1 
plus AFP plus DCP increased remarkably (AUC=0.952) which 
was significantly higher than any single marker and DKK- plus 
AFP and DKK-1 plus DCP (all p<0.001) (Table 2, Supplemen-
tary Fig. 1A, only online). When healthy subjects were exclud-
ed from the controls, similar findings were observed (Table 2, 
Supplementary Fig. 1B, only online).
When identifying early-stage HCC patients from the con-
trols, serum DKK-1 showed a higher AUC than AFP and DCP 
(AUC=0.818 vs. 0.772 and 0.777 for TNM I–II; AUC=0.811 vs. 
0.772 and 0.783 for BCLC A–B, respectively) (Supplementary 
Table 2, only online, Supplementary Fig. 2A and B, only on-
line). When the biomarkers were combined, the triple combi-
nation (DKK-1 plus AFP plus DCP) showed the best accuracy 
(AUC=0.939 for TNM and 0.940 for BCLC, respectively) (Sup-
plementary Table 2, only online, Supplementary Fig. 2A and B, 
only online). Following exclusion of healthy subjects from the Ta
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controls, similar findings were observed (Supplementary Ta-
ble 2, only online, Supplementary Fig. 2C and D, only online).
Correlation between DKK-1 and microscopic HCC 
findings
When correlation analysis was performed between DKK-1 and 
microscopic HCC characteristics using Spearman’s method, 
DKK-1 showed a significant correlation with necroinflamma-
tory activity (coefficient 0.232, p=0.040) and a borderline statis-
tical correlation to satellite nodules (coefficient 0.203, p=0.072) 
(Supplementary Table 3, only online). In contrast, microvessel 
invasion, Edmonson grade, fibrosis, tumor size, and tumor 
number were not significantly correlated to DKK-1 levels (all 
p>0.05).
Diagnostic performance of DKK-1 in subgroups
For the 173 patients with a single HCC (≤5 cm), the diagnostic 
performance of DKK-1 in identifying HCC from controls was 
better than AFP and DCP (AUC=0.781; 95% CI, 0.708–0.853 vs. 
AUC=0.744; 95% CI, 0.668–0.820 for AFP and AUC=0.763; 95% 
CI, 0.691–0.835 for DCP). In addition, the triple marker combi-
nation showed the best accuracy (AUC=0.923; 95% CI, 0.886–
0.961). When patients with HBV-related chronic liver disease 
were selected (n=273), the diagnostic performance of DCP in 
identifying HCC from controls was better than DKK-1 and AFP 
(AUC=0.814; 95% CI, 0.764–0.864 vs. AUC=0.802; 95% CI, 
0.737–0.866 for DKK-1 and AUC=0.772; 95% CI, 0.715–0.828 for 
AFP). Additionally, the triple marker combination showed the 
highest accuracy (AUC=0.942; 95% CI, 0.916–0.968).
After exclusion of 40 healthy subjects from the controls, 
similar findings were observed. DKK-1 was more accurate than 
AFP and DCP in diagnosing single HCC (≤5 cm) (AUC=0.781; 
95% CI, 0.708–0.853 vs. AUC=0.744; 95% CI, 0.668–0.820 for 
AFP and AUC=0.763; 95% CI, 0.691–0.835 for DCP), whereas 
DCP was more accurate than DKK-1 and AFP in diagnosing 
HBV-related HCC (AUC=0.814; 95% CI, 0.764–0.864 vs. AUC= 
0.802; 95% CI, 0.737–0.866 for DKK-1 and AUC=0.772; 95% CI, 
0.715–0.828 for AFP). The triple marker combination showed 
the best accuracy in diagnosing single HCC (≤5 cm) (AUC= 
0.896; 95% CI, 0.848–0.944) and HBV-related HCC (AUC= 
0.942; 95% CI, 0.916–0.968).
DISCUSSION
The survival of HCC patients has improved due to tremen-
dous advances of surgical techniques and perioperative man-
agement; however, the mortality rate is still high. This is pri-
marily due to delayed diagnosis, lack of effective therapies, 
and frequent recurrence and metastasis. Early HCC detection 
gives the opportunity to employ curative treatments such as 
liver transplantation, resection, or local ablative therapy, which 
are the best way to prolong survival.32 Although serum AFP 
and ultrasound have been widely used for HCC diagnosis and 
surveillance, approximately 30–40% of HCC patients are se-
rum AFP-negative and ultrasound detection accuracy for 
HCC is suboptimal.33 As a result, the widespread use of serum 
AFP and ultrasound for HCC surveillance has been continu-
ously questioned.
Because current diagnostic methods are insufficient, it is 
important to identify novel serum biomarkers with high diag-
nostic accuracy to detect and screen early-stage cancers.33 
DKK-1 has recently been recognized as a novel biomarker for 
HCC.23 Conventionally, DKK-1 is known as a secreted glyco-
Table 2. Diagnostic Accuracy of DKK-1, AFP, and DCP in Diagnosing HCC
AUC 95% CI Sensitivity (%) Specificity (%) PPV (%) NPV (%) +LR -LR
HCC vs. all controls
DKK-1 0.829 0.784–0.875 89.4 63.1 82.6 75.3 2.42 0.17 
AFP 0.794 0.746–0.841 65.0 89.5 89.8 64.3 6.21 0.39 
DCP 0.815 0.771–0.859 66.5 93.5 94.1 64.4 10.27 0.36 
DKK-1 plus AFP 0.901 0.869–0.933 88.9 76.2 84.3 82.7 3.73 0.15 
DKK-1 plus DCP 0.927 0.902–0.952 81.4 90.5 93.1 75.6 8.58 0.21 
DKK-1 plus AFP plus DCP 0.952 0.933–0.971 87.9 90.5 93.6 82.7 9.26 0.13 
HCC vs. all controls except healthy subjects
DKK-1 0.825 0.771–0.878 89.4 62.9 77.6 80.5 2.41 0.17 
AFP 0.779 0.729–0.829 65.0 85.8 89.8 56.1 4.59 0.41 
DCP 0.806 0.760–0.853 66.5 91.9 94.7 55.8 8.23 0.36 
DKK-1 plus AFP 0.892 0.854–0.930 88.9 74.8 87.3 77.6 3.53 0.15 
DKK-1 plus DCP 0.924 0.895–0.952 80.5 89.7 94.5 67.4 7.81 0.22 
DKK-1 plus AFP plus DCP 0.948 0.926–0.970 87.9 88.7 94.5 76.8 7.75 0.14 
DKK-1, dickkopf-1; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; AUC, area under receiver operating character-
istic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio.
The optimum predicted probabilities of DKK-1, AFP, DCP, and their combination were derived from their respective ROC curves by maximizing the sum of sensitiv-
ity and specificity and minimizing the overall error.
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protein with a crucial role in limb and head development in 
Xenopus embryos, and as an upstream regulator of T-cell fac-
tor/β-catenin that forms a negative feedback loop in the ca-
nonical Wnt signaling pathway, favoring appropriate cell 
growth.10,34 In normal tissues DKK-1 is hardly expressed, ex-
cept in placenta and embryonic tissues.35 Paradoxically, how-
ever, DKK-1 has been shown to be secreted from some tumor 
into blood stream, suggesting that serum DKK-1 may be a 
useful biomarker for numerous cancers including HCC.36-39 
Serum DKK-1 is an advantageous biomarker because it is 
non-invasiveness, has a simple detection protocol, and is in-
expensive to quantify.40 Therefore, integration of serum DKK-
1 along with serum AFP and sonographic findings may im-
prove and optimize diagnostic work-ups and surveillance 
strategies for HCC.39
Recently, Yu, et al.23 found that DKK-1 expression level was 
associated with β-catenin staining pattern in HCC cell lines, 
and that DKK-1 overexpression correlated with β-catenin cy-
toplasmic/nuclear accumulation in clinical HCC samples. In 
addition, high DKK-1 expression was an independent unfa-
vorable predictor for overall and disease-free survival in HCC 
patients who underwent surgical resection. Our present re-
sults support these observations. Hep3B cells showed high 
DKK-1 mRNA expression and protein secretion. Additionally, 
DKK-1 overexpression raised T-cell factor/β-catenin tran-
scriptional activity and promoted migration of 293 cells. DKK-
1 overexpression promoted invasion, whereas DKK-1 knock-
down inhibited cell growth, migration, protein secretion, and 
invasion in Huh7 cells. These results indicate that DKK-1 ex-
pression has a significant positive association with HCC pro-
gression and metastatic potential. Kuang, et al.41 also observed 
similar influence of DKK-1 on 293 cells. On the other hand, 
however, DKK-1 did not increase cellular invasiveness of 
SNU475 cells.42 The authors also found that DKK-1 did not af-
fect invasion-associated proteases such as matrix metallopro-
tease-2 (MMP-2) that acts on collagen type IV, a major com-
ponent of the Matrigel matrix and that MMP-2 levels were 
unaffected by DKK-1 expression in RT-PCR analysis.42 There-
fore, it appears that the ability of DKK-1 to inhibit Wnt signal-
ing was abrogated in HCC, most likely due to genetic altera-
tions disrupting the central multi-protein complex that controls 
β-catenin stability. However, the exact role of DKK-1 played in 
migration and invasion is unclear, and the molecular mecha-
nism of this controversial phenomenon needs to be further 
explored.
A recent large-scale multicenter study concluded that the 
sensitivity and specificity of serum DKK-1 were satisfactory 
for diagnosing HCC, including early-stage disease and in AFP-
negative patients;39 DKK-1 could distinguish HCC from non-
malignant chronic hepatitis or cirrhosis, particularly in AFP-
positive patients, indicating the potential of DKK-1 as a serum 
biomarker for HCC. The diagnostic accuracy of DKK-1, AFP, 
and DKK-1 plus AFP combination was similar to our findings. 
In our study, the AUC of DKK-1 was higher (AUC 0.825–0.829) 
than AFP and DCP alone. However, when DCP, a biomarker 
widely used in Eastern Asia,43 was combined with DKK-1 and 
AFP together, the diagnostic accuracy of HCC increased sig-
nificantly with an overall AUC of approximately 0.95 and an 
AUC of 0.94 for early-stage HCC. However, the calculated DKK-
1 cutoff value in our study was much lower (1.01 ng/mL vs. 
2.153 ng/mL).39 The exact reason for the DKK-1 cutoff value dif-
ference is unclear. It may be due to heterogeneity of carcino-
genetic mechanisms because of various etiologies of chronic 
liver diseases of our study population. Therefore, further study 
is required to establish an optimal DKK-1 cutoff value.
In our study and in Shen, et al.,39 serum DKK-1 levels were 
statistically similar among control groups regardless of the 
presence of cirrhosis. A study by Tung, et al.44 also showed sta-
tistically similar serum DKK-1 levels between controls with 
and without cirrhosis; however, the DKK-1 transcript level 
was significantly higher in patients with cirrhosis than pa-
tients with chronic hepatitis. Further studies are needed to 
address the discrepancy in DKK-1 serum and transcript levels 
according to the presence of liver cirrhosis. However, it can be 
assumed that DKK-1 transcript level may be correlated to the 
degree of fibrotic burden, which is an important risk factor for 
HCC development. This is in contrast to serum DKK-1 levels, 
which are influenced by apparent HCC development rather 
than high fibrotic burden, an HCC risk factor. In the present 
study, there was, indeed, no correlation between serum DKK-
1 level and fibrosis stage. This might indicate that DKK-1 se-
cretion into the blood stream could be initiated upon hepato-
cyte tumorigenic transformation, and that hepatocytes with 
external stressors favoring HCC development, such as high 
background fibrotic burden, still can control DKK-1 secretion 
despite the high DKK-1 transcript levels. As seen in our study 
and others, this phenomenon might enable to diagnose early-
stage HCC even in the presence of confounding influences 
such as liver cirrhosis.39 Preferential early-stage DKK-1 overex-
pression has already been reported in prostate cancer,45 which 
further supports this hypothesis. However, there was a signifi-
cant correlation between DKK-1 level and necroinflammatory 
activity in our study. The potential influence of necroinflam-
matory activity should be investigated further and, if neces-
sary, compensated for to enhance the accuracy of serum 
DKK-1 in diagnosing HCC.
Tao, et al.46 showed that elevated DKK-1 transcript levels in 
human HCC tissues were significantly correlated with the 
presence of tumor nodules, Edmondson-Steiner grade, and 
the presence of vascular invasion. Furthermore, high DKK-1 
transcript levels were significantly correlated with venous in-
vasion.44 These data indicate the involvement of DKK-1 over-
expression in HCC tissues in HCC invasion and metastasis. In 
our study, however, serum DKK-1 levels showed only a bor-
derline statistical correlation with satellite nodules (p=0.072) 
and no correlation with Edmondson-Steiner grade or vascular 
1305http://dx.doi.org/10.3349/ymj.2015.56.5.1296
Seung Up Kim, et al.
invasion. This may be due to the limited number of patient 
samples with available histological information (n=90). When 
we consider that no macroscopic vascular invasion was iden-
tified in any of our study participants prior to surgical resec-
tion, the influence of DKK-1 overexpression on vascular inva-
sion might have been underestimated. However, because no 
significant correlation between serum DKK-1 level and ve-
nous invasion was observed by Tao, et al.,46 it should be con-
firmed whether the serum DKK-1, rather than the DKK-1 
transcript levels, reflect the invasive and metastatic potential 
of HCC. Interestingly, by Tung, et al.44 observed that tumors 
with DKK-1 expression, established by injection of PLC/PRF/5 
HCC cells into mice, showed an increased microvessel density 
score. Another study showed that DKK-1 mediated endotheli-
al cell activation by suppressing the Wnt/β-catenin pathway.47 
In this study, using an in vivo microvascular remodeling ani-
mal model, DKK-1 significantly increased vascular density 
and vessel diameter in adult rats, indicating that DKK-1 may 
play a role in microvascular remodeling and tumor angiogen-
esis activation, and possibly accounting for DKK-1-mediated 
cancer growth promotion in vivo. Similarly, it has been re-
ported that DKK-1 promotes angiogenic and cartilaginous 
degradation in synovial fibroblasts, accelerating synovial an-
giogenesis and cartilage destruction. These data indicate that 
DKK-1 could be a new therapeutic target for future cancer 
treatment. A molecular-targeted agent similar to sorafenib, 
which suppresses tumor growth and angiogenesis by inhibit-
ing the Raf/MEK/ERK signaling pathway and receptor tyro-
sine kinases,48 could potentially be developed. Based on this 
concept, a very recent study demonstrated that an anti-DKK-1 
monoclonal antibody suppressed cell invasion and growth in 
the lung cancer cell line A549.36 It is highly possible that an 
anti-DKK-1 monoclonal antibody could prevent HCC metas-
tasis and recurrence.
There are several issues that remain unresolved in our 
study. First, the HCC diagnosis obtained in our study was not 
completely based on histopathology. Although histopatholo-
gy remains the gold standard for HCC diagnosis and evalua-
tion, it is difficult to conduct in large populations. Ultrasonog-
raphy and radiological examinations remain the most common 
approach to diagnosing HCC in clinical practices. Furthermore, 
an in-depth correlation analysis between DKK-1 level, HCC 
histological features, and surrounding normal liver parenchy-
ma was not feasible. Second, our study participants were all 
native Korean and HBV was the most common etiology, which 
may limit the generalization of our findings to other ethnici-
ties and chronic liver disease etiologies. Third, the cross-sec-
tional nature of our study is another limitation. Although DKK-
1 expression in HCC tissues has been proved to be a significant 
independent predictor of long-term prognosis, a prospective 
study investigating whether serum DKK-1 can also be used as 
a biomarker for surveillance and prognosis of HCC is needed. 
In conclusion, our study suggests that DKK-1 may be a key 
regulator in HCC progression a promising potential therapeu-
tic target for HCC. We also demonstrated that serum DDK-1 
could be a useful marker for diagnosing HCC, especially in 
combination with AFP and DCP. Further studies are needed 
to confirm whether surveillance program for HCC in patients 
with chronic liver diseases should be adjusted according to 
serum DKK-1 level.
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